Serum alanine aminotransferase is correlated with hematocrit in healthy human subjects

Abstract Background. Serum alanine aminotransferase (ALT) activity is a widely-used surrogate marker for liver injury. However, mild elevation of serum ALT is frequently observed in apparently healthy individuals, making it sometimes challenging to interpret whether this laboratory abnormality is medically benign or serious. To obtain a better understanding of the factors influencing ALT levels, we examined the relation between ALT and a number of anthropometric and biochemistry measurements in humans. Methods. We assessed the associations of ALT with hematocrit (HCT) in 1,200 apparently healthy adults from an Amish population. Multivariate analyses were carried out to determine whether observed associations were independent of other factors known to modulate ALT and HCT, including body mass index (BMI) and sex. The correlation detected in the Amish was then replicated in an independent population sample (N = 9,842) from the National Health and Nutrition Examination Survey (NHANES) III. Results. ALT levels were positively correlated with HCT (r = 0.33, p < 0.0001) in both Amish and NHANES III. The magnitude of association was unchanged after adjustment for BMI, but was reduced by age/sex adjustment to r = 0.18 (p < 0.0001) and r = 0.17 (p < 0.0001) in the Amish and NHANES populations, respectively. HCT accounts for about 3% of the population variation in ALT, which is smaller than the contributions of gender and BMI, but larger than individual blood pressure and cholesterol components. Conclusions. We observed a correlation between ALT and HCT, suggesting that HCT may be a newly identified modulator of ALT in humans.

[1]  Tae Hyeon Kim,et al.  Association of serum alanine aminotransferase and γ-glutamyltransferase levels within the reference range with metabolic syndrome and nonalcoholic fatty liver disease , 2011, The Korean journal of hepatology.

[2]  J. Dufour,et al.  Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN. , 2010, Clinical science.

[3]  J. O’Connell,et al.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.

[4]  Soohyung Park,et al.  Alanine aminotransferase isoenzymes: Molecular cloning and quantitative analysis of tissue expression in rats and serum elevation in liver toxicity , 2009, Hepatology.

[5]  J. O’Connell,et al.  The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study. , 2008, American heart journal.

[6]  Paul J Mills,et al.  Serum aminotransferase levels are associated with markers of hypoxia in patients with obstructive sleep apnea. , 2008, Sleep.

[7]  M. Leshno,et al.  Re‐evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large‐scale population study , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[8]  P. Urdal,et al.  Reference intervals for eight enzymes in blood of adult females and males measured in accordance with the International Federation of Clinical Chemistry reference system at 37°C: part of the Nordic Reference Interval Project , 2004, Scandinavian journal of clinical and laboratory investigation.

[9]  A. Shuldiner,et al.  Murine alanine aminotransferase: cDNA cloning, functional expression, and differential gene regulation in mouse fatty liver , 2004, Hepatology.

[10]  F. Brancati,et al.  The prevalence and etiology of elevated aminotransferase levels in the United States , 2003, American Journal of Gastroenterology.

[11]  A. Shuldiner,et al.  cDNA cloning, genomic structure, chromosomal mapping, and functional expression of a novel human alanine aminotransferase. , 2002, Genomics.

[12]  Lothar Siekmann,et al.  Establishing a Reference System in Clinical Enzymology , 2001, Clinical chemistry and laboratory medicine.

[13]  J. Lott,et al.  Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. , 2000, Clinical chemistry.

[14]  P. Blanc,et al.  Elevated liver enzymes in asymptomatic patients. , 2000, The New England journal of medicine.

[15]  S. Price,et al.  Elevated liver enzymes in asymptomatic patients. , 2000, The New England journal of medicine.

[16]  W. Dietz,et al.  Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. , 2000, The Journal of pediatrics.

[17]  M. Kaplan,et al.  Evaluation of abnormal liver-enzyme results in asymptomatic patients. , 2000, The New England journal of medicine.

[18]  Y. Z. Shen,et al.  Persistent hypertransaminasemia as the presenting findings of muscular dystrophy in childhood. , 1999, Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi.

[19]  K. Asayama,et al.  Relationships between an index of body fat distribution (based on waist and hip circumferences) and stature, and biochemical complications in obese children , 1998, International Journal of Obesity.

[20]  J. Delattre,et al.  Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C , 1998, Hepatology.

[21]  D. Amacher Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. , 1998, Regulatory toxicology and pharmacology : RTP.

[22]  R. Theal,et al.  Evaluating asymptomatic patients with abnormal liver function test results. , 1996, American family physician.

[23]  H. Meiselman,et al.  Mean red cell volume as a correlate of blood pressure. , 1996, Circulation.

[24]  L. McCaig,et al.  Plan and operation of the National Hospital Ambulatory Medical Survey. Series 1: programs and collection procedures. , 1994, Vital and health statistics. Ser. 1, Programs and collection procedures.

[25]  K. Sherman Alanine aminotransferase in clinical practice. A review. , 1991, Archives of internal medicine.

[26]  C. Fink,et al.  Persistent Hypertransaminasemia as the Presenting Finding of Childhood Muscle Disease , 1985, Clinical pediatrics.

[27]  J. Lott,et al.  The enzymology of skeletal muscle disorders. , 1984, Critical reviews in clinical laboratory sciences.